Studies a chemotherapy combination in adults with acute myeloid leukemia after first treatment fails
Observes CLAG chemotherapy in people with acute myeloid leukemia whose first induction did not work.
Plain-language title generated from the registry record
Registry title: A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
Key facts
- Where
- Guanzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with acute myeloid leukemia whose first round of induction chemotherapy did not work. They will be treated again with the CLAG regimen.
- Age
- 14 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia (AML) with first-induction failure, meaning no complete remission after the first induction chemotherapy.
- Earlier treatment
- Must have had a first induction chemotherapy that failed.
Main reasons for not taking part
- Serious infection
- Organ dysfunction
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 65 years old?
Source: NCT05875649, who can take part
Where in China
- Nanfang Hospital of Southern Medical UniversityGuanzhou, ChinaContact: Xuejie Jiang, DoctorNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanfang Hospital, Southern Medical University
- Trial code
- NCT05875649
- Record updated
- 5 July 2023
- Original description
Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients. It was investigated in our study that these patients were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free survival (RFS) was statistically analysed in these patients.Read full original descriptionShow less
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients. It was investigated in our study that these patients were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free survival (RFS) was statistically analysed in these patients.
Inclusion: Acute myeloid leukemia patients with first-induction failure.
Exclusion: Acute myeloid leukemia patients with serious infection and organ dysfunction.